Skip to main content

Table 3 Adverse Events*

From: Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial

Event

Placebo

N = 40

OROS-MPH

N = 40

Restless

2 (5.0)

5 (12.5)

Insomnia

0 (0.0)

5 (12.5)

Headache

1 (2.5)

3 (7.5)

Anorexia

0 (0.0)

3 (7.5)

Vivid Dreams

1 (2.5)

2 (5.0)

Nausea

1 (2.5)

2 (5.0)

Anxiety

0 (0.0)

1 (2.5)

Chest Pain

0 (0.0)

1 (2.5)

Increased Thirst

1 (2.5)

0 (0.0)

Musculoskeletal Discomfort

0 (0.0)

1 (2.5)

Restless Leg

0 (0.0)

1 (2.5)

Weight Loss

0 (0.0)

1 (2.5)

  1. * Adverse events considered to be possibly, probably, or definitely related to study drug are summarized according to treatment group. Overall, there were 6 (15%) subjects in the placebo group and 19 (47.5%) subjects in the methylphenidate group who reported one or more adverse events which were considered to be possibly, probably, or definitely related to study drug.